The bill would establish the right of cancer patients to access advanced care, including precision medicine and genomic testing, in their communities.
The pharmaceutical distributor has launched InspiroGene, a business unit offering logistics and other support for ...
The agency had previously recommended against marketing authorization for the Alzheimer's disease but reconsidered after a review.
The panels assess genes with strong disease links and clinical management guidelines, but the firm offers limited-evidence genes as an add-on option.
This is the first gene therapy for AADC deficiency to receive US regulatory approval and the first that can be administered directly to the brain.
A 31-year-old woman with stage IV breast cancer learns a test ordered more than a year before her diagnosis detected a TP53 ...
NEW YORK – Syros Pharmaceuticals said on Tuesday that its retinoic acid receptor-alpha agonist tamibarotene, which it was testing in combination with azacitidine in patients newly diagnosed with ...
In the deal, Nippon Shinyaku can exclusively sell ATSN-101 in the US and develop and sell it in Japan, while Atsena retains rights to other territories.
NEW YORK – Trace Neuroscience launched on Tuesday, having raised $101 million in a Series A financing round and with a lead therapeutic development program exploring an RNA-based treatment approach ...
A Phase I study of invikafusp alfa presented at SITC provided the rationale to enroll patients with TMB-high, MSI-high, and virus-associated tumors in Phase II.
NEW YORK – Alentis Therapeutics on Tuesday announced that it has raised $181.4 million in a series D financing round, and that it will put the funds toward developing antibody-drug conjugates ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback